Rating: Outperform
12-months Price Target: HK$11.0
Key points
- We expect a stronger 2H21 thanks to stronger volume growth in on- balance-sheet business and platform business.
- New initiatives for partnerships with SaaS providers are long-term growth drivers. Maintain Outperform.
A weak result in 1H21, but 2H21 outlook is positive
- Stronger volume growth into 2H21. After building the platform business with more banks, we believe the balance of its platform business will grow faster, at 80% YoY in 2H21. As such, we expect net profit to grow at 30% YoY in 2H21 while asset quality remains healthy.
- Initiatives in new businesses. We believe SYC’s strategic partnerships with SaaS providers will bring in more factoring businesses and diversify its portfolio. SYC announced that it plans to invest Rmb40 million in LinkedCare, an SaaS provider for dental clinics and aesthetics companies, on 23 June. It has also announced it will invest Rmb21 million in MC Tech, a leading SaaS provider of engineering management solutions for the infrastructure sector on 12 August.
Valuation
- We set our price target at HK$11 based on PB target of 2.4x, compared to 2.1x previously on higher ROE forecasts, and 2022E book of Rmb3.92. The PB multiple of 2.4x is 1SD above its historical average.
評級:跑贏大盤
12個月目標價:11.0港元
要點
-我們預計2h21會更強勁,這要歸功於表內業務和平台業務更強勁的業務量增長。
-與SaaS提供商合作的新計劃是長期增長動力。保持優異的表現。
1h21的結果不佳,但2h21的前景是積極的
- 進入2h21後,成交量增長更強勁。在與更多的銀行建立平台業務後,我們相信其平台業務的餘額將增長更快,在2h21年內同比增長80%。因此,我們預計21財年下半年淨利潤同比增長30%,同時資產質量保持健康。
- 新業務的主動權。我們相信,SYC與SaaS提供商的戰略合作伙伴關係將帶來更多的保理業務,並使其投資組合多樣化。SYC宣佈,計劃於6月23日向LinkedCare投資4000萬元人民幣,LinkedCare是一家為牙科診所和美容公司提供SaaS的公司。該公司還宣佈,將於8月12日向MC Tech投資2100萬元人民幣。MC Tech是一家領先的SaaS基礎設施領域工程管理解決方案提供商。
估值
-我們基於PB目標2.4倍將目標價定為11港元,而此前更高的ROE預期為2.1倍,2022E賬面為3.92元人民幣。PB倍數為2.4倍,比歷史均值高出1SD。